Bristol Myers Squibb won accelerated approval in the US for Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj, plus dexamethasone, to treat adults with advanced multiple myeloma who have received at least one prior line of therapy. The approval also positions iberdomide as the first cleared drug in a new class for myeloma, CELMoDs, built around targeted degradation of cancer-relevant factors through cereblon modulation. In the Phase 3 study underpinning the clearance, Zenbexus-based therapy improved the key endpoint of minimal residual disease (MRD) negativity versus a Velcade (bortezomib) comparator regimen. In a reported interim comparison, 41% of Zenbexus recipients achieved MRD-negative status compared with 21% on Velcade, with overall survival still to be established. Clinically, the FDA clearance extends Zenbexus into the second-line setting alongside established standards including daratumumab combinations. Bristol expects additional results in the coming months, which could determine whether the accelerated approval path can evolve toward full approval.